Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hypertens. May 23, 2015; 5(2): 74-78
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.74
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.74
Symplicity-3 hypertension trial: Basic and clinical insights
Benjamin J Scherlag, Sunny S Po, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States
Author contributions: Both authors contributed to this manuscript.
Conflict-of-interest: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Benjamin J Scherlag, PhD, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 1200 Everett Drive (6E103), Oklahoma City, OK 73104, United States. benjamin-scherlag@ouhsc.edu
Telephone: +1-405-2054457 Fax: +1-405-2717455
Received: September 27, 2014
Peer-review started: September 28, 2014
First decision: December 17, 2014
Revised: February 19, 2015
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: May 23, 2015
Processing time: 236 Days and 9.8 Hours
Peer-review started: September 28, 2014
First decision: December 17, 2014
Revised: February 19, 2015
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: May 23, 2015
Processing time: 236 Days and 9.8 Hours
Core Tip
Core tip: The failure of the Symplicity-3 trial which subjected patients to renal artery denervation to significantly reduce resistant hypertension has been ascribed to many factors. In this review, we focus on the lack of a “biomarker” as a major deficiency in achieving the expected efficacy. We also present experimental and clinical evidence to support the importance of a biomarker to acutely predict long term success of renal artery denervation for effective treatment for drug resistant hypertension.